Design, synthesis, in silico and in vitro evaluation of novel diphenyl ether derivatives as potential antitubercular agents
Diphenyl ether derivatives inhibit mycobacterial cell wall synthesis by inhibiting an enzyme, enoyl-acyl carrier protein reductase (InhA), which catalyses the last step in the fatty acid synthesis cycle of genus Mycobacterium. To select and validate a protein crystal structure of enoyl-acyl carrier protein reductase of Mycobacterium tuberculosis for designing inhibitors using molecular modelling, a cross-docking and correlation study was performed. A series of novel 1-(3-(3-hydroxy-4-phenoxyphenyl)-5-phenyl-4,5-dihydro-1H-pyrazol-1-yl) ethan-1-ones were synthesized from this model and screened for their antitubercular activity against M. tuberculosis H37Rv. Compound PYN-8 showed good antitubercular activity on M. tuberculosis H37Rv (MIC = 4–7 µM) and Mycobacterium bovis (% inhibition at 10 µM = 95.91%). Cytotoxicity of all the synthesized derivatives was assessed using various cell lines, and they were found to be safe. Structure of PYN-8 was also confirmed by single-crystal X-ray diffraction. The molecular modelling studies also corroborated the biological activity of the compounds. Further, in silico findings revealed that all these tested compounds exhibited good ADME properties and drug likeness and thus may be considered as potential candidates for further drug development.
KeywordsTB Diphenylether InhA Molecular docking Correlation study Antitubercular
The authors are thankful to Manipal Academy of Higher Education and Manipal College of Pharmaceutical Sciences for providing necessary supports and facilities to carry out the present research work. Authors are thankful to D’IICT and National Mol Bank (NMB) facility of CSIR-IICT, Hyderabad, India, for the help in biological evaluation of compounds. Authors also thank Manipal-Schrödinger Centre for molecular simulations. This work was funded in part by the Intramural Research Program of the NIH, NIAID.
Compliance with ethical standards
Conflict of interest
The authors confirm that this article content has no conflict of interest.
- 1.WHO (2018) Tuberculosis (TB). WHO, GenevaGoogle Scholar
- 2.World Health Organization (2018) BCG vaccine: WHO position paper, February 2018 – Recommendations. Vaccine 73–96. https://doi.org/10.1016/j.vaccine.2018.03.009
- 3.WHO (2017) Guidelines for treatment of drug-susceptible tuberculosis and patient care. WHO, GenevaGoogle Scholar
- 19.Bhagat S, Sharma R, Sawant DM, Sharma L, Chakraborti AK (2006) LiOH · H2O as a novel dual activation catalyst for highly efficient and easy synthesis of 1, 3-diaryl-2-propenones by Claisen—Schmidt condensation under mild conditions. J Mol Catal A: Chem 244(1–2):20–24. https://doi.org/10.1016/j.molcata.2005.08.039 CrossRefGoogle Scholar
- 24.Barot KP, Jain SV, Gupta N et al (2014) Design, synthesis and docking studies of some novel (R)-2-(4′- chlorophenyl)-3-(4′-nitrophenyl)-1,2,3,5-tetrahydrobenzo[4,5] imidazo [1,2-c]pyrimidin-4-ol derivatives as antitubercular agents. Eur J Med Chem 83:245–255. https://doi.org/10.1016/j.ejmech.2014.06.019 CrossRefGoogle Scholar
- 25.Kaniga K, Cirillo DM, Hoffner S et al (2016) A multilaboratory, multicountry study to determine MIC quality control ranges for phenotypic drug susceptibility testing of selected First-Line Antituberculosis Drugs, Second-Line Injectables, Fluoroquinolones, Clofazimine, and Linezolid. J Clin Microbiol. https://doi.org/10.1128/JCM.01138-16 Google Scholar
- 26.Candice SDM, Feng TS, Van Der Westhuyzen R et al (2015) Aminopyrazolo[1,5-a]pyrimidines as potential inhibitors of Mycobacterium tuberculosis: structure activity relationships and ADME characterization. Bioorganic Med Chem 23:7240–7250. https://doi.org/10.1016/j.bmc.2015.10.021 CrossRefGoogle Scholar
- 31.Solutions BAX BRUKER ADVANCED X-RAY SOLUTIONS SMART APEX User’s Manual, https://www.ndsu.edu/chemistry/files/mcl/smart5_UserManual.pdf